Targeting Cancer Cell Dormancy

Manjili, 2017, Tumor dormancy and relapse: from a natural byproduct of evolution to a disease state, Cancer Res., 77, 2564, 10.1158/0008-5472.CAN-17-0068

Giancotti, 2013, Mechanisms governing metastatic dormancy and reactivation, Cell, 155, 750, 10.1016/j.cell.2013.10.029

Galvao, 2014, Transformation of quiescent adult oligodendrocyte precursor cells into malignant glioma through a multistep reactivation process, Proc. Natl. Acad. Sci. U. S. A., 111, E4214, 10.1073/pnas.1414389111

Malladi, 2016, Metastatic latency and immune evasion through autocrine inhibition of WNT, Cell, 165, 45, 10.1016/j.cell.2016.02.025

Roesch, 2010, A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth, Cell, 141, 583, 10.1016/j.cell.2010.04.020

Chen, 2012, A restricted cell population propagates glioblastoma growth after chemotherapy, Nature, 488, 522, 10.1038/nature11287

Vanner, 2014, Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma, Cancer Cell, 26, 33, 10.1016/j.ccr.2014.05.005

Unnikrishnan, 2017, Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes, Cell Rep., 20, 572, 10.1016/j.celrep.2017.06.067

Meldi, 2015, Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia, J. Clin. Invest., 125, 1857, 10.1172/JCI78752

Puig, 2018, TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence, J. Clin. Invest., 128, 3887, 10.1172/JCI96393

Krall, 2018, The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy, Sci. Transl. Med., 10, 10.1126/scitranslmed.aan3464

Kreso, 2013, Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer, Science, 339, 543, 10.1126/science.1227670

Luskin, 2018, Targeting minimal residual disease: a path to cure?, Nat. Rev. Cancer, 18, 255, 10.1038/nrc.2017.125

Sosa, 2014, Mechanisms of disseminated cancer cell dormancy: an awakening field, Nat. Rev. Cancer, 14, 611, 10.1038/nrc3793

Koebel, 2007, Adaptive immunity maintains occult cancer in an equilibrium state, Nature, 450, 903, 10.1038/nature06309

Teng, 2008, Immune-mediated dormancy: an equilibrium with cancer, J. Leukoc. Biol., 84, 988, 10.1189/jlb.1107774

Nobre, 2018, The different routes to metastasis via hypoxia-regulated programs, Trends Cell Biol., 28, 941, 10.1016/j.tcb.2018.06.008

Romero, 2014, Metastases in immune-mediated dormancy: a new opportunity for targeting cancer, Cancer Res., 74, 6750, 10.1158/0008-5472.CAN-14-2406

Maccalli, 2018, The role of cancer stem cells in the modulation of anti-tumor immune responses, Semin. Cancer Biol., 53, 189, 10.1016/j.semcancer.2018.09.006

Aguirre-Ghiso, 2018, Emerging topics on disseminated cancer cell dormancy and the paradigm of metastasis, Annu. Rev. Cancer Biol., 2, 377, 10.1146/annurev-cancerbio-030617-050446

Manjili, 2014, The inherent premise of immunotherapy for cancer dormancy, Cancer Res., 74, 6745, 10.1158/0008-5472.CAN-14-2440

Sharma, 2010, A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations, Cell, 141, 69, 10.1016/j.cell.2010.02.027

Raha, 2014, The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation, Cancer Res., 74, 3579, 10.1158/0008-5472.CAN-13-3456

Saito, 2010, Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells, Sci. Transl. Med., 2, 17ra9, 10.1126/scitranslmed.3000349

Liau, 2017, Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance, Cell Stem Cell, 20, 233, 10.1016/j.stem.2016.11.003

Abravanel, 2015, Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy, J. Clin. Invest., 125, 2484, 10.1172/JCI74883

Sadasivam, 2013, The DREAM complex: master coordinator of cell cycle-dependent gene expression, Nat. Rev. Cancer, 13, 585, 10.1038/nrc3556

Iness, 2018, The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb, Oncogene, 10.1038/s41388-018-0490-y

Litovchick, 2011, DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly, Genes Dev., 25, 801, 10.1101/gad.2034211

Chen, 2013, Dosage of Dyrk1a shifts cells within a p21-cyclin D1 signaling map to control the decision to enter the cell cycle, Mol. Cell, 52, 87, 10.1016/j.molcel.2013.09.009

Soppa, 2014, The Down syndrome-related protein kinase DYRK1A phosphorylates p27(Kip1) and Cyclin D1 and induces cell cycle exit and neuronal differentiation, Cell Cycle, 13, 2084, 10.4161/cc.29104

MacDonald, 2017, A systematic analysis of negative growth control implicates the DREAM complex in cancer cell dormancy, Mol. Cancer Res., 15, 371, 10.1158/1541-7786.MCR-16-0323-T

Deng, 2009, Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species, Cancer Res., 69, 3317, 10.1158/0008-5472.CAN-08-2903

Ewton, 2011, Inactivation of Mirk/Dyrk1b kinase targets quiescent pancreatic cancer cells, Mol. Cancer Ther., 10, 2104, 10.1158/1535-7163.MCT-11-0498

Hu, 2010, Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by both Mirk/dyrk1b and p130/Rb2, Int. J. Cancer, 129, 307, 10.1002/ijc.25692

Aguirre-Ghiso, 2007, Models, mechanisms and clinical evidence for cancer dormancy, Nat. Rev. Cancer, 7, 834, 10.1038/nrc2256

Aguirre-Ghiso, 2003, ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK), Cancer Res., 63, 1684

Yu-Lee, 2018, Osteoblast-secreted factors mediate dormancy of metastatic prostate cancer in the bone via activation of the TGFbetaRIII-p38MAPK-pS249/T252RB pathway, Cancer Res., 78, 2911, 10.1158/0008-5472.CAN-17-1051

Aguirre Ghiso, 1999, Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling, J. Cell Biol., 147, 89, 10.1083/jcb.147.1.89

Bragado, 2013, TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha/beta signalling, Nat. Cell Biol., 15, 1351, 10.1038/ncb2861

Sosa, 2015, NR2F1 controls tumour cell dormancy via SOX9- and RARbeta-driven quiescence programmes, Nat. Commun., 6, 6170, 10.1038/ncomms7170

Schewe, 2008, ATF6α-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo, Proc. Natl. Acad. Sci. U. S. A., 105, 10519, 10.1073/pnas.0800939105

Ranganathan, 2006, Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase–like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells, Cancer Res., 66, 1702, 10.1158/0008-5472.CAN-05-3092

Jo, 2008, Cancer cell-derived clusterin modulates the phosphatidylinositol 3′-kinase-Akt pathway through attenuation of insulin-like growth factor 1 during serum deprivation, Mol. Cell. Biol., 28, 4285, 10.1128/MCB.01240-07

Vera-Ramirez, 2018, Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence, Nat. Commun., 9, 1944, 10.1038/s41467-018-04070-6

Aqbi, 2018, Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy, Oncotarget, 9, 22113, 10.18632/oncotarget.25197

El-Shennawy, 2018, Coactivation of estrogen receptor and IKKbeta induces a dormant metastatic phenotype in ER-positive breast cancer, Cancer Res., 78, 974, 10.1158/0008-5472.CAN-17-1686

Gawrzak, 2018, MSK1 regulates luminal cell differentiation and metastatic dormancy in ER(+) breast cancer, Nat. Cell Biol., 20, 211, 10.1038/s41556-017-0021-z

Shiozawa, 2008, The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites, Leukemia, 22, 941, 10.1038/leu.2008.48

Shiozawa, 2010, GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche, Neoplasia, 12, 116, 10.1593/neo.91384

Cackowski, 2017, Mer tyrosine kinase regulates disseminated prostate cancer cellular dormancy, J. Cell. Biochem., 118, 891, 10.1002/jcb.25768

Yu-Lee, 2018, Osteoblast-secreted factors mediate dormancy of metastatic prostate cancer in the bone via activation of the TGFβRIII–p38MAPK–pS249/T252RB pathway, Cancer Res., 78, 2911, 10.1158/0008-5472.CAN-17-1051

Kobayashi, 2011, Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone, J. Exp. Med., 208, 2641, 10.1084/jem.20110840

Gao, 2012, The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites, Cell, 150, 764, 10.1016/j.cell.2012.06.035

Sosa, 2011, ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease, Clin. Cancer Res., 17, 5850, 10.1158/1078-0432.CCR-10-2574

Barkan, 2008, Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton, Cancer Res., 68, 6241, 10.1158/0008-5472.CAN-07-6849

Barkan, 2010, Metastatic growth from dormant cells induced by a Col-I–enriched fibrotic environment, Cancer Res., 70, 5706, 10.1158/0008-5472.CAN-09-2356

Viale, 2014, Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function, Nature, 514, 628, 10.1038/nature13611

Rajbhandari, 2017, Autocrine IGF1 signaling mediates pancreatic tumor cell dormancy in the absence of oncogenic drivers, Cell Rep., 18, 2243, 10.1016/j.celrep.2017.02.013

Milanovic, 2018, Senescence-associated reprogramming promotes cancer stemness, Nature, 553, 96, 10.1038/nature25167

Gewirtz, 2009, Autophagy, senescence and tumor dormancy in cancer therapy, Autophagy, 5, 1232, 10.4161/auto.5.8.9896

Wang, 2011, Survivin and escaping in therapy-induced cellular senescence, Int. J. Cancer, 128, 1546, 10.1002/ijc.25482

Fisher, 2017, Persistent bacterial infections and persister cells, Nat. Rev. Microbiol., 15, 453, 10.1038/nrmicro.2017.42

Levin-Reisman, 2017, Antibiotic tolerance facilitates the evolution of resistance, Science, 355, 826, 10.1126/science.aaj2191

Roesch, 2013, Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells, Cancer Cell, 23, 811, 10.1016/j.ccr.2013.05.003

Goldman, 2015, Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition, Nat. Commun., 6, 10.1038/ncomms7139

Holohan, 2013, Cancer drug resistance: an evolving paradigm, Nat. Rev. Cancer, 13, 714, 10.1038/nrc3599

Hangauer, 2017, Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition, Nature, 551, 247, 10.1038/nature24297

Shaffer, 2017, Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance, Nature, 546, 431, 10.1038/nature22794

Vinogradova, 2016, An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells, Nat. Chem. Biol., 12, 531, 10.1038/nchembio.2085

Staberg, 2018, Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B, Mol. Oncol., 12, 406, 10.1002/1878-0261.12174

Dalvi, 2017, Taxane-platin-resistant lung cancers co-develop hypersensitivity to JumonjiC demethylase inhibitors, Cell Rep., 19, 1669, 10.1016/j.celrep.2017.04.077

Risom, 2018, Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer, Nat. Commun., 9, 10.1038/s41467-018-05729-w

Guler, 2017, Repression of stress-induced LINE-1 expression protects cancer cell subpopulations from lethal drug exposure, Cancer Cell, 32, 221, 10.1016/j.ccell.2017.07.002

Ormerod, 1993, Proliferative behaviour of an oestrogen sensitive rat mammary tumour: evidence for a paracrine interaction between tumour and stroma, Br. J. Cancer, 67, 107, 10.1038/bjc.1993.18

Abderrahman, 2018, Rethinking extended adjuvant antiestrogen therapy to increase survivorship in breast cancer, JAMA Oncol., 4, 15, 10.1001/jamaoncol.2017.3510

Davies, 2013, Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial, Lancet, 381, 805, 10.1016/S0140-6736(12)61963-1

Aguirre Ghiso, 2002, Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo, Oncogene, 21, 2513, 10.1038/sj.onc.1205342

Wang, 1998, Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology, Proc. Natl. Acad. Sci. U. S. A., 95, 14821, 10.1073/pnas.95.25.14821

Wang, 2002, Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts, J. Natl. Cancer Inst., 94, 1494, 10.1093/jnci/94.19.1494

El Touny, 2014, Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells, J. Clin. Invest., 124, 156, 10.1172/JCI70259

Chou, 2017, Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer, Gut, 67, 2142, 10.1136/gutjnl-2017-315144

Bollard, 2017, Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma, Gut, 66, 1286, 10.1136/gutjnl-2016-312268

Wiedemeyer, 2010, Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM, Proc. Natl. Acad. Sci. U. S. A., 107, 11501, 10.1073/pnas.1001613107

O’Leary, 2016, Treating cancer with selective CDK4/6 inhibitors, Nat. Rev. Clin. Oncol., 13, 417, 10.1038/nrclinonc.2016.26

Gao, 2012, The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites, Cell, 150, 764, 10.1016/j.cell.2012.06.035

Buczacki, 2018, Itraconazole targets cell cycle heterogeneity in colorectal cancer, J. Exp. Med., 251, 1891, 10.1084/jem.20171385

Beliveau, 2010, Raf-induced MMP9 disrupts tissue architecture of human breast cells in three-dimensional culture and is necessary for tumor growth in vivo, Genes Dev., 24, 2800, 10.1101/gad.1990410

Liu, 2018, STAT3/p53 pathway activation disrupts IFN-beta-induced dormancy in tumor-repopulating cells, J. Clin. Invest., 128, 1057, 10.1172/JCI96329

Ghajar, 2015, Metastasis prevention by targeting the dormant niche, Nat. Rev. Cancer, 15, 238, 10.1038/nrc3910

Linde, 2016, The relationship between dormant cancer cells and their microenvironment, Adv. Cancer Res., 132, 45, 10.1016/bs.acr.2016.07.002

Boyerinas, 2013, Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy, Blood, 121, 4821, 10.1182/blood-2012-12-475483

Saito, 2010, Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML, Nat. Biotechnol., 28, 275, 10.1038/nbt.1607

Di Tullio, 2017, The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia, Nat. Commun., 8, 10.1038/s41467-017-01834-4

Essers, 2009, IFNα activates dormant haematopoietic stem cells in vivo, Nature, 458, 904, 10.1038/nature07815

Sato, 2009, Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion, Nat. Med., 15, 696, 10.1038/nm.1973

Pietras, 2014, Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons, J. Exp. Med., 211, 245, 10.1084/jem.20131043

Boichuk, 2013, The DREAM complex mediates GIST cell quiescence and is a novel therapeutic target to enhance imatinib-induced apoptosis, Cancer Res., 73, 5120, 10.1158/0008-5472.CAN-13-0579

Dittmer, 2017, Mechanisms governing metastatic dormancy in breast cancer, Semin. Cancer Biol., 44, 72, 10.1016/j.semcancer.2017.03.006

Wang, 2018, An acquired vulnerability of drug-resistant melanoma with therapeutic potential, Cell, 173, 1413, 10.1016/j.cell.2018.04.012

McGrath, 2015, Targeting histone lysine methylation in cancer, Pharmacol. Ther., 150, 1, 10.1016/j.pharmthera.2015.01.002

McAllister, 2016, Recent progress in histone demethylase inhibitors, J. Med. Chem., 59, 1308, 10.1021/acs.jmedchem.5b01758

Kruidenier, 2012, A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response, Nature, 488, 404, 10.1038/nature11262

Heinemann, 2014, Inhibition of demethylases by GSK-J1/J4, Nature, 514, E1, 10.1038/nature13688

Dalvi, 2017, Taxane-platin-resistant lung cancers co-develop hypersensitivity to JumonjiC demethylase inhibitors, Cell Rep., 19, 1669, 10.1016/j.celrep.2017.04.077

Suraweera, 2018, Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi, Front. Oncol., 8, 92, 10.3389/fonc.2018.00092

Yang, 2014, Regulation of ferroptotic cancer cell death by GPX4, Cell, 156, 317, 10.1016/j.cell.2013.12.010

Lee, 2012, Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks, Cell, 149, 780, 10.1016/j.cell.2012.03.031

Goss, 2010, Does tumour dormancy offer a therapeutic target?, Nat. Rev. Cancer, 10, 871, 10.1038/nrc2933